OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company’s lead compound, ZYBRESTAT, indicated for the treatment of advanced ovarian cancer and for anaplastic thyroid cancer (ATC), a rare and highly aggressive cancer. The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, to reduce tumor blood flow but which also forms an antiproliferative metabolite. The Company believes that this dual mechanism differentiates OXi4503 from other VDAs and may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.